BAKER BROS. ADVISORS LP

October 17, 2026

Incyte receives mixed analyst updates with price target changes. Incyte saw two recent analyst actions with differing views. Truist Securities raised its price target to $115 while maintaining a Hold rating. Conversely, HC Wainwright reiterated a Buy rating and kept its target at $152. These moves reflect a wide range of expectations among analysts for the stock's future performance.

October 12, 2026

Kodiak Sciences (KOD) Analyst Raises Target, Presents Late‑Stage Data. HC Wainwright & Co. kept its positive stance on Kodiak Sciences and lifted its price target to $126. The company will share clinical results from three late‑stage programs at the American Academy of Ophthalmology conference. Recent reports note the stock is trading at a premium after trial news, while some analysts consider it potentially overvalued. It also appears on a list of health‑care stocks that could face difficulties in Q4.

October 17, 2026

BeOne Medicines Receives Rating Upgrade and Added to Top-Rated List. BeOne Medicines Ltd. has been upgraded to a top rating by analysts. It was also added to a list of top-rated stocks for the week. The upgrade follows recent earnings and infrastructure updates discussed in a broader market analysis. The move may influence investor perception of the company.

October 10, 2026

Celcuity Shares Fall 17% After REVTORPYK Launch and NDA Filing. Celcuity’s stock fell 17.3% after the company announced the launch of its REVTORPYK product in the U.S. and filed a new drug application. The company also said it will present at the European Society for Medical Oncology congress, adding to the mix of upcoming events. With the price near its 14‑day support level of $87.46 and an RSI of 30.1, the move reflects a short‑term reaction to the news rather than a long‑term trend.

October 6, 2026

Madrigal Publishes MAESTRO-NASH Secondary Analysis Data. Madrigal Pharmaceuticals has published data from a pre-specified secondary analysis of its Phase 3 MAESTRO-NASH study in the Journal of Hepatology. The analysis evaluates how patients with altered MASH profiles respond to Rezdiffra. This update provides additional clinical context for the drug's performance in specific patient groups.

October 9, 2026

Denali Therapeutics Shares Test Fair Value Amid Pullback. Denali Therapeutics shares have pulled back, testing the $19.37 support level. The 14‑day RSI sits at 30, indicating a possible oversold condition, while the support_reject signal suggests the level may hold. Analysts average a target of $36.06, with a range of $27 to $42, well above the current price and the 52‑week low of $13.75. The pullback could be seen as a chance to assess fair value.

October 10, 2026

RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates. RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.

October 8, 2026

Kiniksa Reports Strong Growth and Accelerating Earnings. Kiniksa Pharmaceuticals has reported earnings that are accelerating, supporting its growth narrative. Analysts note that the company’s performance shows little room for disappointment, reinforcing confidence in its business model. The company’s recent data underscores its position as a solid growth player in the pharmaceutical sector.

October 16, 2026

Raymond James initiates coverage on Kymera with Outperform rating. Raymond James has started covering Kymera Therapeutics, assigning an Outperform rating and a price target of $140. This new analyst note adds to the current consensus, which has an average target of $139.35 from 23 analysts. Recent discussions also question whether the company's pipeline is over-hyped or developing into a major therapeutic success.

September 27, 2026

TRDA sees institutional interest from NVIDIA and Merck. The Benzinga report notes that institutional investors linked to NVIDIA and Merck have increased their positions in TRDA. This activity signals growing confidence in the company’s pipeline and may attract additional attention from other investors. The move comes as TRDA trades near the lower end of its 52‑week range, providing a potential entry point for those monitoring the stock.

October 1, 2026

KALA Bio Signs LOI to Acquire Telehealth Platform. KALA Bio shares surged 57% after hours following the announcement of a non-binding letter of intent to acquire a nationwide telehealth platform. The target company has generated approximately $48 million in sales since inception. Additionally, the company signed a separate agreement to resell genetic testing products through a U.S. DNA testing platform.

October 5, 2026

VTVT Completes Phase 3 Cadisegliatin Trial Enrollment. vTv Therapeutics announced that enrollment for its phase 3 cadisegliatin trial in type 1 diabetes has been completed. The milestone moves the program closer to the next study stage and may influence future clinical and commercial outlook. The stock is currently trading near a long‑standing support level that has been tested many times.